Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
TERT telomerase reverse transcriptase
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
ZAP70 zeta chain of T cell receptor associated protein kinase 70
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • Staurosporine
  • Fostamatinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Negative regulation of FLT3
  • ATP
  • Dasatinib
  • XL228
  • K-00546
  • Fostamatinib
BAG1 BAG cochaperone 1
  • Regulation of HSF1-mediated heat shock response
  • (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
BCAR3 BCAR3 adaptor protein, NSP family member
CASP3 caspase 3
  • Activation of caspases through apoptosome-mediated cleavage
  • SMAC (DIABLO) binds to IAPs
  • SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
  • Apoptotic cleavage of cellular proteins
  • SMAC, XIAP-regulated apoptotic response
  • Apoptosis induced DNA fragmentation
  • Degradation of the extracellular matrix
  • Signaling by Hippo
  • NADE modulates death signalling
  • Stimulation of the cell death response by PAK-2p34
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Apoptotic cleavage of cell adhesion proteins
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Other interleukin signaling
  • Pamidronic acid
  • Acetylsalicylic acid
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • Emricasan
  • Incadronic acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
  • Glycyrrhizic acid
CDK6 cyclin dependent kinase 6
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Alvocidib
  • (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
  • Fisetin
  • Palbociclib
  • Ribociclib
  • Abemaciclib
CNR1 cannabinoid receptor 1
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Dronabinol
  • Nabilone
  • Ricinoleic Acid
  • SLV319
  • V24343
  • AVE-1625
  • Rimonabant
  • Cannabidiol
  • Propacetamol
  • Otenabant
  • Tetrahydrocannabivarin
  • Medical Cannabis
  • Nabiximols
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
CTTN cortactin
  • RHO GTPases activate PAKs
  • Clathrin-mediated endocytosis
DAPK3 death associated protein kinase 3
  • Caspase activation via Dependence Receptors in the absence of ligand
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid
  • (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
  • Fostamatinib
DNAJA3 DnaJ heat shock protein family (Hsp40) member A3
EPHA2 EPH receptor A2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
  • Fostamatinib
FES FES proto-oncogene, tyrosine kinase
  • Signaling by SCF-KIT
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Fostamatinib
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Erdafitinib
  • Pemigatinib
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
GRB14 growth factor receptor bound protein 14
  • Tie2 Signaling
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid

Page 3 out of 7 pages